| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | tivozanib | GDSC1000 | pan-cancer | AAC | 0.0054 | 0.9 |
| mRNA | Crizotinib | GDSC1000 | pan-cancer | AAC | -0.0092 | 0.9 |
| mRNA | KH-CB19 | CTRPv2 | pan-cancer | AAC | -0.007 | 0.9 |
| mRNA | CAY10576 | CTRPv2 | pan-cancer | AAC | -0.006 | 0.9 |
| mRNA | BRD-K30748066 | CTRPv2 | pan-cancer | AAC | -0.018 | 0.9 |
| mRNA | BRD-K29313308 | CTRPv2 | pan-cancer | AAC | 0.0053 | 0.9 |
| mRNA | Bryostatin 1 | GDSC1000 | pan-cancer | AAC | -0.0051 | 0.9 |
| mRNA | KIN001-260 | GDSC1000 | pan-cancer | AAC | -0.0045 | 0.9 |
| mRNA | Doxorubicin | GDSC1000 | pan-cancer | AAC | -0.005 | 0.9 |
| mRNA | L-685458 | CTRPv2 | pan-cancer | AAC | 0.005 | 0.9 |